Effective Xiaflex administration for Peyronie disease involves back-to-back injections and achieving an erection with the first injection of each series. Optimizing dosage, dilution, and incorporating ...

Five-fraction SBRT showed noninferiority to conventional radiotherapy in localized prostate cancer, with 95.8% of patients free from failure at five years. SBRT offers a shorter treatment duration, ...

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS. In this interview, ...

"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that ...

The NRG-GU011 trial evaluates relugolix plus SBRT versus SBRT alone in men with PSA recurrence and PSMA-PET-detected metastases. The study addresses whether targeted radiation can delay hormone ...

Ga-PSMA and F-Fluciclovine PET/CT significantly increased radiotherapy target volumes post-prostatectomy, with F-Fluciclovine leading to more prostate bed boosts. F-Fluciclovine showed higher prostate ...

UGN-102's NDA acceptance marks a potential first FDA-approved treatment for LG-IR-NMIBC, with a PDUFA date of June 13, 2025. The phase 3 ENVISION trial demonstrated a 79.6% complete response rate at 3 ...

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by ...

Oliver Sartor, MD, discusses how a 70-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) represents a typical candidate for PSMA-targeted imaging and potential ...

PSMA-PET imaging enables molecular-level detection of prostate cancer cells, often before CT or MRI abnormalities are visible. Sensitivity of PSMA-PET/CT in recurrent prostate cancer can reach 97% ...

The application is supported by data from the pivotal phase 3 ARANOTE trial. Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of darolutamide (Nubeqa) in ...

Simultaneous F rhPSMA-7.3 PET/MRI imaging demonstrated a 93.75% PPV in detecting recurrent prostate cancer lesions. The study involved 29 patients, with 79% experiencing changes in radiation therapy ...